clinical trial

November 5, 2019

Nektar Launches Phase 1 Trial Testing NKTR-255 in Non-Hodgkin’s Lymphoma, Multiple Myeloma

News

Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial assessing the safety and efficacy of its investigational agent NKTR-255 in people with relapsed or refractory non-Hodgkin’s lymphoma and multiple ... Read more

October 24, 2019October 24, 2019

Follicular Lymphoma Patients Being Recruited for Phase 2 Trial of Aliqopa-Rituximab Combo

News

A Phase 2 clinical trial is recruiting patients with untreated follicular lymphoma — the most common type of non-Hodgkin’s lymphoma — to study a combination of Aliqopa (copanlisib) and rituximab. The trial ... Read more

July 23, 2019

NantKwest Launches Phase 1 Trial to Assess Investigational Cell Therapy for B-cell Lymphomas

News

NantKwest is launching the first-in-human Phase 1 clinical trial assessing the effects of its investigational CD19 t-haNK cell therapy in people with locally advanced B-cell lymphoma. The trial follows the ... Read more

July 12, 2019July 12, 2019

Dosing Begins in Study of TP-0903, With or Without Imbruvica, for Advanced CLL and SLL

News

Dosing with the investigational therapy TP-0903 has begun in patients with previously treated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in an ongoing Phase 1/2 trial, its developer, Tolero Pharmaceuticals, announced. ... Read more

May 3, 2019

Forty Seven, Genentech Continue to Test Triple Immunotherapy Combo in DLBCL

News

Forty Seven and Genentech are extending their agreement to include a third clinical trial evaluating a combination of the investigational 5F9 plus Rituxan (rituximab) and Tecentriq (atezolizumab) in patients with diffuse large B-cell lymphoma (DLBCL). The decision builds on prior ... Read more

April 9, 2019

First CTCL Patients Enrolled in Phase 2 Trial of Topical Treatment WP1220

News

The Phase 2 clinical trial assessing Moleculin Biotech‘s STAT3 inhibitor, WP1220, for the topical treatment of cutaneous T-cell lymphoma (CTCL) lesions has enrolled the first two participants. The trial, to assess WP1220‘s safety and ... Read more

February 19, 2019

Poteligeo Proves Safe, Effective for ATL Patients in Clinical Setting

News

Poteligeo (mogamulizumab), an approved treatment for relapsed or refractory adult T-cell leukemia-lymphoma (ATL) patients in Japan, is also safe and effective in a real-world clinical setting, a postmarketing surveillance study found. ... Read more

February 13, 2019February 14, 2020

X4 Pharmaceuticals Launches Phase 1b Trial Testing Mavorixafor-Imbruvica Combo for Waldenström’s Macroglobulinemia

News

X4 Pharmaceuticals has launched a Phase 1b trial to assess the safety and tolerability of mavorixafor (X4P-001), in combination with Imbruvica (ibrutinib), for the treatment of people with Waldenström’s macroglobulinemia ... Read more

October 10, 2018October 10, 2018

9 in 10 Heavily Treated CTCL Patients See Benefits with IPH4102, Phase 1 Trial Shows

News

IPH4102, Innate Pharma’s investigational antibody, reduced tumor volume in 36% of patients with cutaneous T-cell lymphoma (CTCL) in a Phase 1 trial. Patients were heavily pre-treated, having received at least two ... Read more

March 14, 2018March 14, 2018

G100-Keytruda Combo Shows Higher Response in Follicular Lymphoma Patients in Phase 2 Trial

News

Data from a Phase 2 clinical trial showed that combining Immune Design‘s experimental immunotherapy G100 with fractioned, low-dose radiation and Keytruda (pembrolizumab) leads to higher response rates in follicular lymphoma patients, the company announced. The randomized ... Read more